Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii
Open Access
- 1 February 2017
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (2)
- https://doi.org/10.1128/aac.01745-16
Abstract
We asked whether beta-lactamase inhibitors (BLIs) increased the activity of daptomycin (DAP) against methicillin-resistant Staphylococcus aureus (MRSA), the peptide antibiotic colistin (COL) against the emerging Gram-negative nosocomial pathogen Acinetobacter baumannii , and the human host defense peptide cathelicidin LL37 against either pathogen. DAP and LL37 kill curves were performed with or without BLIs against MRSA, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA (hVISA). COL and LL37 kill curves were performed against A. baumannii . Boron-dipyrromethene (BODIPY)-labeled DAP binding to MRSA grown with the BLI tazobactam (TAZ) was assessed microscopically. The combination of COL plus TAZ was studied in a murine model of A. baumannii pneumonia. TAZ alone lacked in vitro activity against MRSA or A. baumannii . The addition of TAZ to DAP resulted in a 2- to 5-log 10 reduction in recoverable MRSA CFU at 24 h compared to the recoverable CFU with DAP alone. TAZ plus COL showed synergy by kill curves for 4 of 5 strains of A. baumannii tested. Growth with 20 mg/liter TAZ resulted in 2- to 2.5-fold increases in the intensity of BODIPY-DAP binding to MRSA and hVISA strains. TAZ significantly increased the killing of MRSA and A. baumannii by LL37 in vitro . TAZ increased the activity of COL in a murine model of A. baumannii pneumonia. Classical BLIs demonstrate synergy with peptide antibiotics. Since BLIs have scant antimicrobial activity on their own and are thus not expected to increase selective pressure toward antibiotic resistance, their use in combination with peptide antibiotics warrants further study.Keywords
Funding Information
- HHS | National Institutes of Health (1U01AI124316-01)
- HHS | National Institutes of Health (1U01AI124316-01)
This publication has 22 references indexed in Scilit:
- β-Lactam Antibiotics Targeting PBP1 Selectively Enhance Daptomycin Activity against Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2013
- Altering the Proclivity towards Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus Using Combinations with Other AntibioticsAntimicrobial Agents and Chemotherapy, 2012
- Ampicillin Enhances Daptomycin- and Cationic Host Defense Peptide-Mediated Killing of Ampicillin- and Vancomycin-Resistant Enterococcus faeciumAntimicrobial Agents and Chemotherapy, 2012
- The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility TestsJournal of Clinical Microbiology, 2011
- Use of Antistaphylococcal -Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin BindingClinical Infectious Diseases, 2011
- Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic StewardshipClinical Infectious Diseases, 2009
- Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?Journal of Antimicrobial Chemotherapy, 2005
- Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptibleacinetobacter baumanniiFEMS Microbiology Letters, 1995
- Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillinAntimicrobial Agents and Chemotherapy, 1991
- Pharmacokinetics of sulbactam in humansAntimicrobial Agents and Chemotherapy, 1983